DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS 
Korean national cohort of 12,866 ADHD children found methylphenidate use ≥365 days linked to 46.5% overweight/obesity rate in early adulthood versus 35.0% in matched controls. Height reductions were statistically significant but clinically small (under 1 cm), while BMI increases showed meaningful clinical impact with adjusted odds ratios elevated for both overweight and obesity.
🔬 CLINICAL CONSIDERATIONS
- Long-term methylphenidate therapy associates with 11.5 percentage point increase in adult overweight/obesity prevalence, representing clinically significant metabolic impact beyond statistical findings.
- Height suppression effects proved modest (under 1 cm difference), suggesting growth concerns may be overstated relative to weight trajectory risks in ADHD population.
- ADHD diagnosis itself carries metabolic risk independent of stimulant exposure, indicating baseline disorder characteristics contribute to adult weight outcomes beyond medication effects.
- Effect persisted after adjusting for comorbidities and concurrent medications, strengthening evidence that methylphenidate exposure duration specifically influences adult BMI trajectories.
🎯 PRACTICE APPLICATIONS
- Plot serial BMI percentiles every 3-6 months during methylphenidate therapy to detect early weight trajectory changes.
- Counsel families at initiation that extended stimulant use may paradoxically increase long-term obesity risk despite acute appetite suppression.
- Coordinate nutrition referrals for ADHD patients on stimulants exceeding 1 year continuous use, particularly those showing BMI percentile increases.
- Document height velocity annually but reassure families that stature impacts are minimal compared to metabolic considerations.
More in Child & Adolescent Psychiatry
